(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of -17.29% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.86%.
Maxcyte's revenue in 2024 is $41,288,000.On average, 2 Wall Street analysts forecast MXCT's revenue for 2024 to be $3,555,993,398, with the lowest MXCT revenue forecast at $3,457,071,180, and the highest MXCT revenue forecast at $3,654,915,615.
In 2025, MXCT is forecast to generate $4,566,041,303 in revenue, with the lowest revenue forecast at $4,227,623,190 and the highest revenue forecast at $4,904,459,415.